Dade Behring Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Dade Behring Inc.
Recent regulatory events and dealmaking highlight an increase in the pace of innovation in rapid infectious disease testing.
The firm's health-care division bought private next-generation sequencing firm NEO New Oncology for an undisclosed amount.
Although prostate problems have plagued men for many years, the growing elderly population is now driving an unprecedented increase in caseloads and a corresponding need for improved treatments. One of the primary concerns is the rise in prostate cancer diagnoses. With more than two million American men currently living with prostate cancer and more than 200,000 new cases diagnosed each year, the market for diagnostic and therapeutic products to address this disease is substantial; more than $2 billion in the US in 2007.
Brief summaries of recent product and company developments in the device industry, including: developments in continuous glucose monitoring, new liability conerns for device companies, medtech acquisitions in 2007, and the 2008 IPO market.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Hematology, Coagulation
- Therapeutic Drug Monitoring